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ABSTRACT (100 Word Limit) 159 
In this trans-ethnic multi-omic study we reinterpret the genetic architecture of blood pressure to 160 
identify genes, tissues, phenome, and medication contexts of blood pressure homeostasis. We 161 
discovered 208 novel common blood pressure SNPs and 53 rare variants in GWASs of systolic, 162 
diastolic and pulse pressure in up to 776,078 participants from the Million Veteran Program 163 
(MVP) and collaborating studies, with analysis of the blood pressure clinical phenome in MVP. 164 
Our transcriptome-wide association study detected 4,043 blood pressure associations with 165 
genetically-predicted gene expression of 840 genes in 45 tissues, and murine renal single-cell 166 
RNA sequencing identified upregulated blood pressure genes in kidney tubule cells.   167 
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Decades of scientific evidence implicate elevated blood pressure in the etiology of 168 
cardiovascular disease, including coronary artery disease, peripheral arterial disease, and stroke, 169 
as well as renal and ocular damage. Elevated blood pressure accounts for at least 13% of annual 170 
deaths worldwide1,2. The risk of death from ischemic heart disease and stroke increases linearly 171 
with systolic blood pressure (SBP) and diastolic blood pressure (DBP) elevations greater than 172 
115 mmHg and 75 mmHg, respectively3. Recent treatment guidelines emphasize the benefit of 173 
blood pressure-lowering strategies, including drug treatments, at lower thresholds of SBP or 174 
DBP4. These guidelines also identify a substantial patient population who are untreated or 175 
undertreated for elevated blood pressure, or do not have sufficient treatment response to anti-176 
hypertensive drugs and highlight the need to identify new gene targets for therapies5. 177 
Large-scale genome-wide association studies (GWAS) have reported over 250 loci associated 178 
with blood pressure traits, establishing that blood pressure traits are complex with many genetic 179 
determinants of modest effect6–27. Large blood pressure GWAS meta-analyses combine evidence 180 
from many cohorts and identify genetic determinants of SBP, DBP and pulse pressure levels. 181 
Regulatory effects may account for substantial heritability in GWAS studies, and GWAS 182 
sentinel SNPs are enriched for regulatory SNPs compared to the proportion of the genome 183 
containing regulatory elements28–30. Most blood pressure SNPs are noncoding, are not in strong 184 
linkage disequilibrium (LD) with trait-associated coding variants, and are often found in 185 
regulatory elements12. Several methods were recently developed to use multiple SNPs to perform 186 
gene-based tests of association between imputed gene expression levels and phenotypes, which 187 
are tissue-specific and provide interpretable direction and magnitude of effects31–34  188 
In this trans-ethnic study, we meta-analyzed data for 459,777 participants, 318,891 from the 189 
Million Veteran Program (MVP) and 140,886 from the UK Biobank (UKB)12. We subsequently 190 
performed independent replication in 316,301 participants from the International Consortium for 191 
Blood Pressure (ICBP)25 and Vanderbilt University’s BioVU cohort to study common variant 192 
associations with minor allele frequency (MAF) greater than 1% (Figure 1). With 318,891 193 
participants from the MVP as the discovery sample, we conducted two studies of rare variants, 194 
one focused on variants across the genome with independent replication in 445,360 participants 195 
from UKB and the other focused on exonic regions with replication in up to 420,704 participants 196 
from the Blood Pressure-International Consortium of Exome chip studies (BP-ICE) consortium. 197 
We report associations between blood pressure and common and rare SNPs, and blood pressure 198 
and genetically predicted gene expression (GPGE). We also evaluated gene-drug relationships 199 
and toxicities, conducted a phenome-wide association study (PheWAS) of blood pressure genetic 200 
risk scores, conducted pathway and tissue gene set enrichment analyses, and performed studies 201 
to identify murine kidney cell types where expression for implicated genes is increased. 202 
RESULTS 203 
MVP participants (N = 318,891), representing the majority of the discovery sample size, were 204 
predominantly male (91.5%), and were administratively identified as non-Hispanic whites 205 
(69.1%), with non-Hispanic blacks, Hispanics, non-Hispanic Asians and non-Hispanic Native 206 
Americans representing 18.8%, 6.7%, 0.77% and 0.85% of the population respectively 207 
(Supplementary Table 1). Blacks were older on average [mean = 60.6 years, (standard deviation 208 
= 11.4)], followed by whites [58.9 (12.6)], Native Americans [58.9 (12.6)], Hispanics [52.7 209 
(14.5)], and Asians [48.6 (16.1)]. Approximately half of the MVP participants were on 210 
antihypertensive medications and a quarter had diabetes. Participants from the UKB interim 211 
release, originating from UKB application number 236, (N = 140,886) were also included in the 212 
discovery analysis; their characteristics are reported elsewhere12.  213 
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Single Variant Analyses 214 
Common Variants 215 
We identified a total of 505 independent loci (201 novel loci, 304 previously reported) associated 216 
with one or more blood pressure traits: SBP, DBP and pulse pressure. Among the previously 217 
reported loci, 216 were associated with SBP, 76 with DBP and 208 with pulse pressure (Table 1; 218 
Figure 2a-c; Supplementary Tables 2a-c) and were not evaluated for replication. Sentinel 219 
variants from loci that were deemed to be novel by comparison with the GWAS catalog 220 
(accessed March 2017 or literature report; P-value < 1 × 10-6 in the discovery phase; greater than 221 
500 kb from a known sentinel SNP; r2 ≤ 0.1 with known sentinel SNPs) and up to two proxies (N 222 
= 1,478) were carried forward for replication with the ICBP consortium. Replicated variants had 223 
consistent directions of effect in the discovery and replication phases, had P-values < 0.05 in the 224 
replication stage, and had meta-analysis (discovery + replication) P-values < 5 × 10-8 (Online 225 
methods for details). These replicated SNPs represented 201 novel loci and included 124 loci for 226 
SBP, 4 loci for DBP and 123 loci for pulse pressure (Supplementary Tables 3a-c). Comparison 227 
of mean effect estimates of blood pressure-trait increasing alleles showed that, on average, novel 228 
loci had smaller magnitudes of association (0.24, 0.14, and 0.18 mmHg per allele for SBP, DBP 229 
and pulse pressure, respectively) than known loci (0.32, 0.27, and 0.27 mmHg per allele, for 230 
SBP, DBP and pulse pressure, respectively; Table 1). Sentinel SNPs at all independent loci from 231 
meta-analysis of common variants explained 3.56%, 1.06% and 3.72% of the total variance for 232 
SBP, DBP and pulse pressure respectively. Novel variants contributed to 0.80%, 0.24% and 233 
0.72% of the total variance explained by all independent loci for SBP, DBP, and pulse pressure, 234 
respectively.  235 
Identification of conditionally independent signals using discovery meta-analysis results 236 
identified an additional 37 SNPs from 29 loci (7 novel, 3 within the boundaries of both known 237 
and novel loci) as significant in one or more blood pressure traits (Supplementary Table 4). 238 
Trans-ancestry Comparisons 239 
To update the observations reported by Franceschini et al. in 20139, where 29 SNP effects on 240 
blood pressure reported by Ehret et al. in 201135 were consistent across European, African, East 241 
Asian, and South Asian ancestries, we compared known and novel loci across ancestral groups in 242 
MVP. We examined the correlation between effect sizes in white, black, and Hispanic samples. 243 
Observed correlations of effect sizes between race/ethnic groups in MVP were weaker than those 244 
previously reported, though the directions of effects were largely consistent (Supplementary 245 
Figure 1; Supplementary Table 5).  246 
Rare Exonic Variants 247 
Rare exonic variants (MAF < 1%) with suggestive evidence of association (P-value < 1 × 10-6) 248 
from the discovery sample were queried for replication in populations from BioVU (N = 17,277) 249 
and the BP-ICE (Nmax = 420,704) consortium. Eighteen variants were on the exome chip and 250 
available for final meta-analysis. Ten missense variants from seven genes were associated with 251 
blood pressure traits (P < 5 × 10-8; Table 2). Five variants were associated with SBP and/or DBP 252 
(rs141328069 [PDE3A; ArgGln], rs139491786, [SLC9A3R2; ArgTrp], rs61760904 [RRAS; 253 
AspAsn], rs73181210 [PHC3; LysGlu], rs3085380 [DBH; Gly  Ala]) with consistent 254 
directions of effect for SBP and DBP. Three rare variants from COL21A1 (rs118079907 255 
[CysArg], rs200999181 [GlyVal], and rs2764043 [LeuPro]) and one variant from NOX4 256 
(rs139341533; LeuPhe) were significantly associated with pulse pressure but not with SBP or 257 
DBP and in fact had opposite directions effect for SBP and DBP. SNPs in RRAS, DBH, and one 258 
of the three SNPs in COL21A1 (rs200999181) have been previously reported22–24. Average 259 
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absolute values of effect estimates for SBP, DBP and pulse pressure in these variants were 1.52, 260 
0.63, and 1.50 mmHg per allele, respectively.  261 
We conditioned these SNPs on the sentinel common variant in each respective locus, where 262 
available, in the MVP whites discovery sample and compared effect estimates before and after 263 
conditioning. SNP rs139491786 in SLC9A3R2 showed a >50% reduction in effect size after 264 
conditioning on common variant rs140869992 (r2 = 0.35). Effect sizes for all other rare exonic 265 
variants were considered independent as no substantial differences in effect estimates were 266 
observed after conditioning (Supplementary Table 6). 267 
All Rare Variants 268 
Discovery analysis in the MVP samples only (excluding UKB) identified 1,684 rare variants 269 
with suggestive evidence for association across the three blood pressure traits; 1,066 of these 270 
variants were available for meta-analysis in UKB. We observed statistically significant 271 
associations (P-value < 5 × 10-8) between 48 rare variants and one or more blood pressure traits. 272 
We identified 40 SNPs for pulse pressure, eight SNPs for SBP, and two SNPs for DBP 273 
(Supplementary Table 7). Average absolute values of effect estimates for SBP, DBP and pulse 274 
pressure were 9.67, 2.33 and 13.89 mmHg per allele, respectively. The missense variants from 275 
NOX4 (rs139341533), SLC9A3R2 (rs139491786), and COL21A1 (rs200999181, rs2764043) 276 
were evaluated in the both the exonic and rare-variant analyses separately (Table 2; 277 
Supplementary Table 7).  278 
Transcriptome-Wide Association Analyses 279 
Common variants from the final meta-analysis were used to evaluate the associations between 280 
blood pressure traits and genetically predicted gene expression (GPGE) levels across 44 281 
Genotype-Tissue Expression Project (GTEx)36 tissues and the human kidney reference described 282 
by Ko et al.37, using S-PrediXcan31. We identified statistically significant GPGE associations for 283 
1,552 gene-tissue pairs with SBP, 521 with DBP, and 1,970 for pulse pressure (Supplementary 284 
Tables 8a-c; Supplementary Figures 2-4). We identified 409 genes with this analysis that would 285 
not be identified if SNPs were annotated using the nearest gene. MTHFR was the top result from 286 
SBP and showed decreasing SBP with increasing GPGE in skeletal muscle, aorta, and several 287 
other tissues.  288 
Murine Kidney Single Cell Sequencing Analysis 289 
Homologs of human genes identified as significant in the S-PrediXcan analysis of kidney tissue 290 
were investigated for kidney cell type-specific RNA expression using single cell sequencing in 291 
murine kidney cells. Cells were clustered into 11 groups representing structural features and 292 
other cell types found in the kidney. Sixteen of the 28 genes were most expressed in any of the 293 
five tubule-related cell types: proximal tubules, loop of Henle, distal convoluted tubules, 294 
collecting duct principal cells and collecting duct intercalated cells (Figure 3; Supplementary 295 
Table 9a-c). Cross-referencing protein expression levels in the Human Protein Atlas38 confirmed 296 
findings from murine kidney, including higher expression of CDC16, SRR, SFXN2 and CLCN6 297 
proteins in tubules compared to glomeruli (Supplementary Table 10). 298 
Assessment of Gene-Drug Relationships  299 
To better understand how genes identified in the study relate to medications, associations 300 
identified from the GPGE analyses were investigated for overlap with gene targets of known 301 
antihypertensive medications, non-antihypertensive medications, and medications with adverse 302 
drug events (ADEs) for hypertension and hypotension (Supplementary Tables 11-14). A total of 303 
2,177 tissue- and blood pressure trait-specific drug-gene interactions were identified in this 304 
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analysis. Of these, there were 617 unique drug-gene interactions, with 175 (28.36%) with 305 
antagonistic effects.  306 
The genes PDE3A, PSMB9, and SH2B3 targeted by the non-antihypertensive drugs theophylline, 307 
carfilzomib, and pazopanib, respectively, have adverse drug events of either hypo- or 308 
hypertension and increase blood pressure with increasing GPGE. The most significant gene in S-309 
PrediXcan targeted by an antihypertensive medication was CLCN6 (SBP β = -2.76, P-value = 310 
8.14 × 10-45) in tibial artery tissue (Supplementary Table 11). The gene most significant in S-311 
PrediXcan with a positive effect size and targeted by a non-antihypertensive medication was 312 
PRKAR2B (β = 1.38, P-value = 1.39 × 10-81) in aortic artery tissue identified from the pulse 313 
pressure analysis (Supplementary Table 12). The gene most significant in S-PrediXcan with a 314 
positive effect size and targeted by a drug with an ADE for hypertension was PSMB9 (pulse 315 
pressure β = 0.42, P-value = 7.57 × 10-9) in tibial artery tissue (Supplementary Table 13).  316 
PheWAS with blood pressure Genetic Risk Scores 317 
To systematically evaluate pleiotropy between genetic predictors of blood pressure-traits and 318 
diseases throughout the phenome, we performed PheWAS using blood pressure-trait weighted 319 
genetic risk scores (w-GRS) separately in self-reported/administratively identified non-Hispanic 320 
white, non-Hispanic black, and Hispanic individuals in the MVP.  We used all known and novel 321 
common sentinel SNPs from the final meta-analysis and trait-specific weights from the UKB 322 
discovery sample to generate w-GRSs for each blood pressure trait and regressed PheWAS 323 
outcomes from MVP onto those scores, adjusted for the top 10 genetic principal components. 324 
Eighty-eight of 1,813 phenotypes were significantly associated with any w-GRSs at a 325 
Bonferroni-corrected P-value threshold < 2.76 × 10-5 (Supplementary Table 15). Hypertension 326 
(smallest P-value < 1 × 10-305), essential hypertension (smallest P-value < 1 × 10-305) and 327 
hypertensive heart and/or renal disease (smallest P-value = 3.3 × 10-173) were the top associations 328 
for each of the nine w-GRSs. PheWAS associations were consistent across race/ethnic groups 329 
(Supplementary Figure 5). Associations with phenotypes in the circulatory system (N = 52) 330 
accounted for more than 50% of the significant results in whites. The phenotype groups with the 331 
next most associations were endocrine/metabolic (N = 28), genitourinary (N = 10) and 332 
hematopoietic (N = 6).  333 
Among significant associations, 45 were significant for all three w-GRSs, 10 were significant for 334 
both SBP and DBP, and 15 were significant for both SBP and pulse pressure, demonstrating 335 
substantial overlap between signals captured by genetically predicted blood pressure traits 336 
(Supplementary Figure 6; Supplementary Table 15). Thirteen associations were significant only 337 
for the pulse pressure w-GRS, of which five were the diabetes sequelae ophthalmic 338 
manifestations, neurological manifestations, diabetic retinopathy, other abnormal glucose, and 339 
polyneuropathy. Aortic and other aneurysms were only associated with the DBP w-GRS, but not 340 
with other w-GRSs.  341 
Enrichment and pathway analyses 342 
We evaluated whether statistically significant genes from S-PrediXcan analyses were enriched in 343 
one or more tissues. Compared to other tissues, aorta showed the greatest evidence for 344 
enrichment of significant genes across all three traits (SBP P-value = 3.7 × 10-3; DBP P-value = 345 
5.7 × 10-3; and pulse pressure P-value = 1.2 × 10-9; Supplementary Table 16). We provided 346 
sentinel SNPs from known and novel loci for each blood pressure trait (Supplementary Tables 347 
17a-c and 18a-c) to DEPICT39 and detected enrichment of 36 tissues across seven systems for 348 
pulse pressure (FDR < 5%). The greatest enrichment was seen in arteries (P-value = 3.43 × 10-10) 349 
and 11 out of the 36 tissues are grouped in the cardiovascular system (Supplementary Table 17c). 350 
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Gene-set enrichment of the pulse pressure GWAS results identified 574 enriched gene-sets (FDR 351 
< 5%); abnormal vascular smooth muscle morphology (MP:0005592; P-value = 1.47 × 10-8) was 352 
the top gene set (Supplementary Table 18c).  353 
We prioritized statistically significant results from the S-PrediXcan aorta tissue analyses for all 354 
three traits and investigated pathways using the Ingenuity Pathway Analysis (IPA) software 355 
(Supplementary Figures 7-9). Cardiovascular Disease (SBP P-value = 7.2 × 10-6; pulse pressure 356 
P-value = 9.53 × 10-4), and Cardiovascular System Development and Function (SBP P-value = 357 
7.7 × 10-5; pulse pressure P-value = 9.53 × 10-4) networks were among the top enriched 358 
networks. Notable features in the SBP IPA results included the TGF-β and NOTCH signaling 359 
pathways (Supplementary Figure 7), while pulse pressure IPA results featured atherosclerosis 360 
genes including CDH13, TCF7L2, PHACTR1 and MTHFR (Supplementary Figure 9).  361 
Convergence of evidence 362 
We collated evidence for genes that were associated in two or more types of investigations that 363 
inform relevant gene targets (rare coding variants, predicted gene expression, single-cell 364 
sequencing expression enrichment, and drug query) and highlight noteworthy genes (Table 3). 365 
We identified 46 known and 7 novel genes satisfying this criterion, including three Mendelian 366 
hypo- or hypertension genes and 15 genes targeted by antihypertensive medications. Nine genes 367 
were expressed in murine kidney tubule cell types and 19 genes were identified in at least one 368 
aorta IPA network.  369 
DISCUSSION  370 
We present results from multi-omic analyses of a trans-ethnic GWAS consortium for blood 371 
pressure traits. By incorporating large sample sizes, bioinformatics, and measures of gene 372 
expression, we re-interpret the genetic architecture of blood pressure and identify tissues and 373 
anatomical features where blood pressure genes exert effects. Interrogation of gene-drug 374 
relationships and toxicities for GPGE associations provides additional evidence for known and 375 
novel blood pressure genes, and suggests genes as potential leads for drug development and 376 
repurposing potential for existing drugs. We emphasize the utility of large-scale blood pressure 377 
GWAS as a requisite starting point for analyses providing insight into clinical factors, genetic 378 
etiology, pathophysiology, and pharmacology of blood pressure homeostasis. 379 
The MVP comprises US military veterans, and has an overrepresentation of male and black 380 
participants compared to the US population. We had a larger collection of Hispanic participants 381 
than the largest previous study of blood pressure traits in that population13, and almost twice the 382 
number of black participants as the largest previous study of African ancestry populations10. 383 
Although consistent, our comparison of SNP effects on blood pressure traits demonstrated a 384 
lower correlation between race/ethnic groups than Franceschini et al.9; however, the effects we 385 
compared were much more subtle than the first 29 blood pressure SNPs detected by Ehret et al.6. 386 
We compared the effects on clinical outcomes of genetically-imputed blood pressure traits in a 387 
PheWAS, and observed consistent effects between racial/ethnic groups in MVP. These results 388 
support the previous observation9  that genetic effects on blood pressure of common SNPs are 389 
consistent between populations, and suggest that an increasing burden of blood pressure-390 
increasing alleles has a similar effect on health across white, black, and Hispanic populations. 391 
Evidence from S-PrediXcan and DEPICT identified arteries as the tissue type with greatest 392 
evidence for gene enrichment. These findings agree with results from Warren et al. 201712, 393 
which reported arteries as the top tissue from a DEPICT analysis of blood pressure traits, and 394 
also with results from Gamazon et al. 201840, which reported aorta as the top PrediXcan tissue 395 
with highly enriched gene signals for SBP. The lack of enrichment of genes in other relevant 396 
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tissues such as the kidney maybe due to the smaller sample of kidney tissues available in 397 
prediction training sets or that tissue-specific gene expression is differentially enriched. 398 
The SBP IPA analysis highlights genes linked to TGF-β and notch signaling pathways including 399 
FURIN, GUCY1A3 (Syn: GUCY1A1), and GUCY1B3. (Table 3; Supplementary Figure 7). GPGE 400 
of FURIN in the aorta was positively associated with SBP. This effect is likely mediated by 401 
furin-induced activation of pro-TGF-β1 to TGF-β1, which works along with the RAS pathway to 402 
increase blood pressure41–44. Predicted expression of FES, a gene <1 kb upstream of FURIN, is 403 
inversely associated with SBP in aorta, coronary artery, tibial artery, and kidney (Supplementary 404 
Table 8a), suggesting the presence of two proximal blood pressure loci with different regulatory 405 
mechanisms. Naproxen, a non-steroidal anti-inflammatory drug, has an inhibitory effect on FES 406 
(Supplementary Tables 12 and 13) and hypertension is one of its known side-effects45. Findings 407 
highlight the importance of the role of soluble guanylyl cyclase (sGC) expression via the Notch 408 
signaling pathway in the mouse aorta on hypertension46. GUCY1A3 and GUCY1A1 encode 409 
subunits of sGC which is a major nitric oxide (NO) receptor in the vascular wall46–48. As 410 
mediators of the vasodilatory effects of NO, increased expression of these genes predicted a 411 
decrease in SBP in aorta (Table 3 and Supplementary Table 8a).  412 
To understand how genetically-predicted blood pressure is associated with the clinical 413 
phenome, we calculated w-GRSs for each blood pressure trait and evaluated them with a 414 
PheWAS (Supplementary Table 15). The pulse pressure w-GRS was associated with diabetic 415 
complications, while w-GRS for SBP or DBP had fewer diabetes-related associations. Pulse 416 
pressure is an independent predictor of cardiovascular disease and incident diabetes49,50. 417 
Elevated pulse pressure is a marker for arterial stiffness51, which is positively associated with 418 
diabetic retinopathy and neuropathy52. These findings are supported by the pulse pressure IPA 419 
results where the top cardiovascular gene network includes at least four genes which may 420 
directly or indirectly mediate arterial stiffness or atherosclerosis, including TCF7L2, CDH13, 421 
PHACTR1, and MTHFR (Supplementary Figure 9)53–59. Our finding of a positive association 422 
between the DBP w-GRS and aortic and other aneurysms supports evidence from a previous 423 
study of 1.25 million individuals where an association between DBP and aortic aneurysm was 424 
reported60. Our study is the first to provide evidence for a genetic etiology for this observation. 425 
Convergent evidence from multiple analyses identified several blood pressure genes with strong 426 
biologic importance, including PDE3A and novel genes RXFP2 and ADK. RXFP2 is a receptor 427 
for the hormone relaxin61, which causes vasodilation, increases cardiac output and renal 428 
perfusion, and has been evaluated in clinical trials as a treatment for acute heart failure62–64. 429 
RXFP2 is expressed in multiple tissues, which likely underlies the multiple physiological effects 430 
of the relaxin hormone throughout the circulatory system65.  431 
The product of ADK, adenosine kinase, catalyzes the transfer of gamma-phosphate from 432 
adenosine triphosphate to adenosine to form adenosine monophosphate and has widespread 433 
effects on multiple systems including cardiovascular, nervous and respiratory systems66. 434 
Adenosine terminates supraventricular tachycardia (SVT) involving the atrioventricular (AV) 435 
node and has been attributed to cardiac brady-arrhythmias67,68. Intravenous adenosine injection in 436 
humans induces vasodilation and systemic hypotension69, and is the primary drug used in the 437 
treatment of stable narrow-complex SVT70. It is known to reduce blood pressure and blood 438 
pressure variability in rats, and its actions are mediated through adenosine receptors71. We show 439 
a positive association between GPGE of ADK and SBP and pulse pressure in aortic tissue 440 
(Supplementary Tables 8a and 8c), consistent with the known directional effects of adenosine on 441 
blood pressure.  442 
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PDE3A is targeted by a wide variety of inhibitors for indications including congestive heart 443 
failure, hypertension, and heart disease. The PDE3A inhibitor theophylline used to treat chronic 444 
obstructive pulmonary disease has a hypotension ADE, which is consistent with the effects of 445 
increased gene expression in our analysis (Supplementary Tables 12 and 13). The autosomal 446 
dominant Mendelian condition Hypertension and Brachydactyly Syndrome (HTNB; OMIM: 447 
112410) is caused by at least six distinct rare PDE3A mutations72,73. HTNB features include 448 
brachydactyly type E, severe salt-independent but age-dependent hypertension, increased 449 
fibroblast growth rate, neurovascular contact at the rostral-ventrolateral medulla, altered 450 
baroreflex blood pressure regulation, and death from stroke before age 50 years when 451 
untreated74,75. Associations between common variants in the PDE3A locus and blood pressure 452 
have been reported previously25,26.  453 
A novel aspect of this study is the incorporation of single-cell gene expression data from cells 454 
derived from murine kidneys. We show that a majority of blood pressure genes identified by S-455 
PrediXcan analyses in human kidneys are enriched in tubule cell types derived from murine 456 
kidneys. This observation suggests that genes detected through GPGE associations and expressed 457 
in tubules, including SRR, ACHE, SFXN2 and CLCN6, may play a role in blood pressure 458 
regulation. Several lines of evidence implicate the SRR gene, while the nearest gene annotation 459 
strategy identifies SMG6 as associated with blood pressure at this locus. A SNP in SMG6, 460 
rs216172, has been associated with coronary artery disease76; however, this SNP is an eQTL for 461 
SRR and not for SMG6 (GTEx portal). SNPs near SRR have been associated with type 2 diabetes 462 
(T2D) and T2D mediated arterial stiffness53. ACHE terminates signal transduction at the 463 
neuromuscular junction by rapid hydrolysis of acetylcholine released into the synaptic cleft77. 464 
Inhibition of acetylcholinesterase is an effective treatment for orthostatic hypotension, especially 465 
in patients with supine hypertension78. Dimetacrine, a tricyclic antidepressant, and 466 
decamethonium, a muscle relaxant, have inhibitory effects on ACHE and are not currently 467 
prescribed as anti-hypertension medications. 468 
This work helps to  clarify the complex MTHFR locus by providing unique tissue-specific 469 
evidence for several genes in the region in relation to blood pressure79,80. In addition to MTHFR, 470 
our study provides evidence for the role of NPPA (novel missense variant; Table 2), NPPB 471 
(GPGE association with SBP and pulse pressure in the left ventricle; Supplementary Tables 8a 472 
and 8c), and CLCN6 (inverse association in kidney S-PrediXcan, and enrichment in murine 473 
kidney; Supplementary Tables 8a-c and 9a-c) in blood pressure. NPPA and NPPB are 474 
exclusively expressed in the heart and have biological functions that include natriuresis, diuresis, 475 
vasorelaxation, inhibition of renin and aldosterone secretion, and play a key role in 476 
cardiovascular homeostasis81. GPGE of CLCN6, a putative chloride antiporter82, was consistently 477 
associated across blood pressure traits. CLCN6 is targeted by the antihypertensive medication 478 
chlorthalidone, and NPPB is targeted by the antihypertensive medication carvedilol 479 
(Supplementary Table 11). Findings for this locus highlight that effects of multiple associated 480 
genes from the same locus may vary by tissue type, and several nearby genes with very different 481 
biological functions may jointly contribute to the trait of interest. 482 
In conclusion, we applied multiple post-GWAS analyses to identify genes with effects on blood 483 
pressure regulation. We report hundreds of novel SNPs and genes, several with strong biological 484 
plausibility, and tissue-specific gene associations with directions of effect. We provide insight 485 
into the natural experiments of gene regulation and direct perturbation of proteins by mutation 486 
with regard to effects on blood pressure, which enhances the biological understanding of blood 487 
pressure traits. Our study identifies a refined set of genes that often have coordinated expression 488 
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across multiple tissues that may have relevance to blood pressure traits and these gene-tissue 489 
pairs are prime candidates for causal investigation.   490 
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FIGURE LEGENDS 774 
 Figure 1. Study design schematic. Flowchart depicting strategy for the three association 775 
analysis strategies (common, rare, and exonic variants), as well as replication selection criteria 776 
and numbers of samples and SNPs by stage. Subsequent TWAS and PheWAS analyses using 777 
common variant summary statistics are also presented. SBP, systolic blood pressure; DBP, 778 
diastolic blood pressure; PP, pulse pressure; SNP, single nucleotide polymorphism; ICBP, 779 
International Consortium for Blood Pressure; BP-ICE, Blood Pressure-International Consortium 780 
for Exomechip; BioVU, Vanderbilt University biorepository; ADE, adverse drug events 781 
 782 
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Figure 2. Manhattan plots summarizing discovery and replication meta-analysis for (a) 783 
SBP, (b) DBP, and (c) pulse pressure. Manhattan plot of the discovery + replication meta-784 
analysis. The y axis shows the –log10 P-values and the x axis shows the chromosomal positions. 785 
The horizontal red line represents the thresholds of P-value = 5 × 10-8 for genome-wide 786 
significance. SNPs in red are in previously identified loci (includes discovery only; Neff-max = 787 
459,670 for SBP, 459,093 for DBP, and 459,305 for pulse pressure) whereas SNPs in orange are 788 
in novel loci (includes discovery + replication; Neff-max = 760,226 for SBP, 767,920 for DBP, 789 
and 759,768 for pulse pressure). All P-values are computed for associations between 790 
genotyped/imputed SNPs and blood pressure traits as dependent variables in multivariable 791 
adjusted logistic regression models. SBP, systolic blood pressure; DBP, diastolic blood pressure 792 
 793 
Figure 3. Mapping blood pressure-associated genes to murine kidney cell type clusters for 794 
(a) SBP, (b) DBP, and (c) pulse pressure. Average expression level of GWAS/eQTL defined 795 
genes in murine kidney cell types. Expression levels were determined in 43,745 kidney cells 796 
derived from seven mice. Mean expression values of the genes were calculated in each cluster. 797 
Color scheme is based on Z-score distribution obtained from two-sided Wald test. Z-scores are 798 
not corrected for multiple comparisons. Each row represents one gene and each column is single 799 
cell type cluster (as defined by Park et al.) on the heat map. Endo: endothelial, vascular, 800 
descending loop of Henle, Podo: podocyte, PT: proximal tubule, LOH: ascending loop of Henle, 801 
DCT: distal convoluted tubule, CD-PC: collecting duct principal cell, CD-IC: CD intercalated 802 
cell, Fib: fibroblast, Macro: macrophage, Neutro: neutrophil, NK: natural killer cell. 803 
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Table 1. Summary of known and novel loci achieving statistical significance from analysis of common variants. 804 
  Known Loci Novel Loci   
    All novel P-value** Tier 1 Tier 2 Tier 3 
N Loci Average  Effect* (SD) N Loci
Average  
Effect* (SD)   N Loci
Average  
Effect* (SD) N Loci
Average  
Effect* (SD) N Loci
Average  
Effect* (SD) 
SBP 216 0.32 (0.15) 124 0.24 (0.12) 1.03x10-7 26 0.29 (0.16) 39 0.23 (0.12) 59 0.22 (0.07) 
DBP 76 0.27 (0.15) 4 0.14 (0.02) 7.73x10-13 2 0.14 (0.02) 0 0 2 0.14 (0.002) 
PP 208 0.27 (0.15) 123 0.18 (0.09) 9.57x10-12 21 0.19 (0.08) 46 0.18 (0.09) 56 0.17 (0.09) 
Total 304 -   201 -    - -  - -  - - 
Known loci: known loci were only tested for significance in the discovery sample (N = 459,776). Novel loci: tested in discovery 805 
sample and ICBP (N-Discovery = 459,776; N-replication = 299,024; Total N = 758,800) *Mean beta = average and standard deviation 806 
of the absolute value of beta-estimates for each trait; **Represents P-value from two-sample t-test comparing mean beta for known 807 
loci and all novel loci. SBP = systolic blood pressure; DBP = diastolic blood pressure; PP = pulse pressure; Tier 1 = First tier 808 
significance criteria: GWAS significance at discovery + replication passing Bonferroni threshold + consistent directions of 809 
associations between discovery and replication sets + GWAS significant at final meta-analysis; Tier 2 = Second tier significance 810 
criteria: GWAS significance at discovery + replication P-value < 0.05 + consistent directions of associations between discovery and 811 
replication sets + GWAS significant at final meta-analysis; Tier 3 = Third tier significance criteria: Suggestive significance at 812 
discovery (P-value < 1 × 10-6 & > 5 × 10-8) + replication P-value < 0.05 + consistent directions of associations between discovery and 813 
replication sets + GWAS significant at final meta-analysis. 814 
815 
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Table 2. Associations between missense variants identified in collaboration with consortia evaluating exonic variants and rare-816 
variants.   817 
SNP Chr:BP Gene 
Amino 
Acid 
Change
EA/ 
RA 
EAF 
SBP  DBP    Pulse Pressure  
Effect P-value Neff Info Effect P-value Neff info 
Effec
t P-value Neff info 
rs141325069 12:20769270 PDE3A RQ A/G 0.0030 1.42 8.7x10-9 700,771 0.99 0.72 2.7 x10-5 700,575 0.99 0.76 5.2x10-5 700,391 0.99 
rs139491786#† 16:2086421 SLC9A3R2 RW T/C 0.0068 -1.92 4.6x10-21 651,069 0.97 -1.32 1.9x10-22 651,707 0.97 -0.64 1.9x10-5 649,540 0.96 
rs61760904* 19:50139932 RRAS DN T/C 0.0073 1.16 1.1x10-12 844,155 0.99 0.52 8.8x10-7 843,327 0.98 0.67 2.0x10-8 843,773 0.99 
rs73181210 3:169831268 PHC3 KE T/C 0.0107 0.86 3.7x10-8 845,000 0.93 0.61 1.8x10-9 844,834 0.93 0.23 4.2x10-2 842,255 0.93 
rs3025380* 9:136501756 DBH GA C/G 0.0046 -1.14 1.9x10-8 864,699 0.98 -0.83 7.2x10-10 863,755 0.98 -0.32 3.0x10
-2 864,042 0.98 
rs139341533# 11:89182666 NOX4 LF A/C 0.0037 -0.81 2.1x10-4 851,884 0.99 0.22 1.2x10-1 850,481 0.99 -0.93 8.7x10-9 852,260 0.99 
rs115079907 6:55924005 COL21A1 CR T/C 0.0023 1.26 2.1x10-3 837,965 0.99 -0.58 3.2x10-2 831,917 0.97 1.70 1.4x10-8 830,745 0.97 
rs200999181*# 6:55935568 COL21A1 GV A/C 0.0014 1.90 9.2x10-6 724,111 0.80 -1.04 4.3x10-4 718,225 0.79 2.96 3.3x10-21 724,615 0.80 
rs2764043# 6:56035643 COL21A1 LP A/G 0.0016 -1.53 1.9x10-5 812,384 0.93 0.35 1.4x10-1 814,667 0.93 -1.93 2.4x10-13 810,623 0.93 
rs138582164 8:95264265 GEM R. A/G 0.0011 3.25 2.1x10-7 633,292 1.00 0.13 7.6x10-1 632,884 1.00 3.16 6.0x10-12 632,845 1.00 
rs202102042^ 1:11907171 NPPA RQ T/C 0.0004 3.86 3.1x10-7 765,853 0.78 
 
1.06 3.1x10-2 765,853 0.78
 
3.20 2.4x10-8 765,853 0.78 
 
*SNPs have been previously reported in the literature. #SNPs were identified in two different replication strategies: exonic set and 818 
rare-variant set. ^ SNPs were replicated in the rare variants replication set. †SNP was no longer significant after conditioning on 819 
GWAS sentinel SNP at this locus. GWAS significance set at P < 5 × 10-8) For SNPs that were available in both rare-variant and 820 
exonic analyses, table reports results with the largest sample size.  Neff represents the effective N available for each SNP, defined by 821 
the sum of N* imputation info score across each analysis strata.   EA, effect allele; RA, reference allele, EAF, effected allele 822 
frequency.823 
824 
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Table 3. Converging evidence across analyses. 825 
Gene Locus Novelty 
Common/Rare 
Coding  SNPs 
Nearest 
Gene 
CVD Tissues 
(S-PrediXcan) 
Mouse 
Kidney 
Single Cell 
Clusters 
Supplementary 
Drug Table 
Reference 
Count/Drug Aorta IPA 
ADK novel rs34868542 ADK --↑x-xx ST12 12 PP;SBP 
FDFT1e novel NA NA x-↑↑↑xx  ST11, ST12 
LOVASTATIN, 
LAPAQUISTAT 
ACETATE 
- 
PLAUe novel rs34868542 ADK ↑-xxxx- ST11, ST12 55 - 
PSMB7 novel NA NA xx-x↑xx ST12 5 - 
PSMB9 novel NA NA x--x↑x- ST12, ST13 5 - 
RAB10 novel NA NA xx-xxx↑ Immune - 
RXFP2 novel rs9603376 RXFP2 xxxx-↑x ST12 4 - 
ACHEb known rs374292503 Intergenic -x↓↓↓↓↓ Tubules ST12 56 DBP 
ACP2e known rs11039216 SLC39A13 ↑↑xx-xx  ST11 
ATENOLOL, 
VERAPAMIL - 
AGERa known rs1061808 AGPAT1 x↑↑x↑-x ST12 VITAMIN B12 DBP 
ARL3 known rs140473396 CNNM2 ↑↑↑↑↑xx ST12 CHEMBL384759 - 
ARVCF known rs2240716 ARVCF xx↓x↓xx ST12, ST13 3 PP 
AS3MT known rs140473396 CNNM2 --↑↑↑x- ST12 LK-204545 - 
ATP1B1f known rs4656180 NME7 xx↑x-x- ST12 4 - 
BACE1e known rs573455 CEP164 xxxx-↑x ST11, ST12 28 - 
BAG6 known rs1800629 TNF --↑↑↑xx ST13 CARBAMAZEPINE - 
BCAR1e known rs12449170 CFDP1 -x↑x↑x- ST11 CELECOXIB SBP 
C4Ab known rs1061808 AGPAT1 ↓↓↓↓↓↓x ST12 IMMUNE GLOBULIN DBP 
CDC16 known rs11617448 CDC16 ↑↑↑↑↑↑↑ Tubules - 
CDC25A known rs35979968 MAP4 ↓↓↓↓↓-↓ Tubules SBP 
CEP68 known rs74181299 CEP68 ↑↑↑-↑-↑ Tubules PP 
CLCN6e known rs6669371 CLCN6 xx-x↓-↓ Tubules ST11, ST13, ST14 9 - 
COL21A1c known 
rs12203179/ 
rs115079907, 
rs200999181, 
rs2764043 
COL21A1 xxx-↓x↓    - 
CYP21A2a known rs1061808 AGPAT1 xx↑x↑xx ST13 KETOCONAZOLE - 
FES known rs2071382 FES -x↓↓↓-↓ Immune ST13 NAPROXEN SBP 
FURIN known rs2071382 FES xx↑xxxx ST12 3 SBP 
GFAPe known rs6503413 NMT1 xx↓xxx- ST11, ST13, ST14 28 - 
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GUCY1A3e known rs3796592 GUCY1A3 xx↓xxx↓ ST11, ST14 6 SBP 
GUCY1B3e known rs3796592 GUCY1A3 xx↓xx-x ST11, ST14 6 SBP 
HLA-Bg known rs1800629 TNF ---↑--x ST12, ST13 6 - 
HLA-DRB5b known rs1061808 AGPAT1 --↓↓↓-x ST12 1D09C3 - 
IGFBP3e known rs10260816 Intergenic x↑-xxxx  ST11, ST14 
FLUOROURACIL, 
CELECOXIB - 
MADDe known rs11039216 SLC39A13 ↑↑-x--x ST11 VERAPAMIL - 
NME6 known rs35979968 MAP4 x--x↑↑↑ Glomerulus - 
NMT1 known rs6503413 NMT1 --↑↑↑-↑ Immune ST12 CHEMBL355497 SBP 
NOTCH4b known rs1061808/ rs139341533 AGPAT1 x↓↓x↓↓x  ST12 
NIROGACESTAT, 
REGN-421 DBP 
NOV known rs11783703 NOV x↓↑x↑xx ST12 INSULIN DBP 
NPPBef known rs6669371 CLCN6 x↓xxxxx  ST11, ST14 
OXYMETHOLONE, 
CARVEDILOL - 
NPR3e known rs12656497 NPR3 xxxxx↑x ST11, ST12, ST13 4 - 
NSF known rs80335285 GOSR2 ↑↑-↑-xx ST12 BITOSCANATE - 
NT5C2 known rs140473396 CNNM2 xx↑x↑↓x ST12 4 SBP 
OPRL1 known rs6090040 TCEA2 ↓x↓x↓↓x ST12 13 - 
PDE3A known rs60691990/ rs141325069 Intergenic xxx-xx-  ST12, ST13 19 - 
PKN2 known rs12035750 GTF2B x-xxxx↑ Tubules ST12 3 - 
POC1B known rs11105354 ATP2B1 x--x-x↑ Tubules - 
PRKAR2Bd known rs12705390 AF086203 x-↑x--x ST12 5 ALL 
SBF2e known rs58068637 SWAP70 xx↓xxxx ST11 PAROXETINE - 
SFXN2 known rs140473396 CNNM2 -↑x-xx↑ Tubules - 
SLC12A2e known rs6595838 FBN2 x↑xx-xx ST11, ST12 6 - 
SLC4A7 known rs2643826 SLC4A7 xx↓xxx↓ Immune   SBP 
SRR known rs12952051 SMG6 ↑↑-↑↑↑↑ Tubules ST12 PYRIDOXAL PHOSPHATE, SERINE - 
THBS2a known rs533414974 Intergenic xx↑-↑xx  ST12 
BEVACIZUMAB, 
CORTICOTROPIN DBP 
TUBB1 known rs6026739 ZNF831 xxxxxx↑   ST12, ST13 10 - 
 826 
Selection criteria: evidence from at least 2 categories (coding variant gene, S-PrediXcan gene, gene implicated in mouse kidney single-cell 827 
expression, or drug target) and from at least 4 analyses. Gene = Gene showed enriched expression in one or more cell type in murine kidney 828 
single-cell RNA sequencing experiment, or was significant in genetically predicted gene expression analysis for any of the 45 tissues; Novel = 829 
Indicator variable denotes whether variants in a given gene region have previously been reported in genome-wide association studies of blood 830 
pressure traits. Sentinel SNPs = Sentinel SNP from common or rare variant analyses from each independent locus. Nearest Gene = Column 831 
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reports genes that would have been identified if the nearest gene annotation strategy was used to link GWAS significant variants.  CVD Tissues = 832 
Column identifies genes that were significantly associated with genetically predicted gene expression and blood pressure traits (using S-833 
PrediXcan) in the following cardiovascular related tissues: heart atrial appendage, heart left ventricle, aorta, coronary artery, tibial artery, adrenal 834 
gland and kidney. Up (down) arrow indicates a positive (negative) association between GPGE and at least one blood pressure trait. Dash indicates 835 
data was not significant and x indicates data were unavailable. For a full-set of tissue specific results, see Supplementary Tables 8a-8c. Mouse 836 
kidney single-cell clusters = Column highlights the cell-type in which specific genes were enriched in murine single-cell RNA sequencing 837 
expression analyses. Supplementary Drug Table Reference =  References the supplementary tables containing the gene-drug relationship. 838 
Count/Drug = Column summarizes drugs targeting genes when the number of drugs is ≤2 or the total number of drugs targeting the gene when the 839 
number of drugs is >2 which were identified to interrelate with the gene from the following databases: Guide to Pharmacology Interactions, 840 
Drugbank, PharmGKB, TDG Clinical Trials, TEND, and/or ChEMBL Interactions. Aorta IPA = Trait(s) for which the gene was identified in the 841 
aorta IPA network, SBP = systolic blood pressure; DBP = diastolic blood pressure; PP = pulse pressure; 842 
aGenetically predicted expression of these genes was positively associated with pulse pressure, inversely associated with DBP, and 843 
non-significant for SBP 844 
bGenetically predicted expression of these genes was positively associated with DBP, inversely associated with pulse pressure, and 845 
non-significant for SBP 846 
cGenetically predicted expression of these genes was positively associated with DBP and inversely associated with SBP and pulse 847 
pressure 848 
dGenetically predicted expression of these genes was positively associated with SBP and pulse pressure and inversely associated with 849 
DBP 850 
eTargeted by an antihypertensive medication 851 
fMendelian gene for hypertension 852 
gMendelian gene for hypotension 853 
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ONLINE METHODS 854 
We conducted a multi-stage GWAS of common and rare variants in over 750,000 participants. 855 
We then performed additional bioinformatics analyses of GPGE for blood pressure traits, 856 
evaluated cell types where associated genes are expressed, performed a phenome-wide 857 
association study of genetic risk scores for blood pressure traits from the electronic health 858 
records of MVP participants, and screened known drugs to evaluate potential for repurposing and 859 
validate observed associations. A flow chart for analyses is presented in Figure 1.  860 
Discovery Cohorts 861 
The Million Veteran Program 862 
The Million Veteran’s Program (MVP) is a large cohort of fully consented participants who were 863 
recruited from the patient populations of 63 Department of Veterans Affairs (VA) medical 864 
facilities. The MVP is recruited at VA hospitals from men and women who are veterans of the 865 
US armed forces. It is enriched with African American and Hispanic participants compared with 866 
the general US population, and males are overrepresented. Across race groups, the average age 867 
ranged between 49 for Asian and 61 for black participants (Supplementary Table 1). Average 868 
BMI ranged between 27.8 for Asian and 30.9 for Native Americans. The proportion of males 869 
ranged between 87% for Native Americans and 93% for whites. Average SBP ranged between 870 
132 mmHg for Asians and 140 mmHg for blacks, average DBP ranged between 81 mmHg for 871 
Asians and 85 mmHg for Blacks, and average pulse pressure ranged between 51 mmHg for 872 
Asians and 57 mmHg for whites. The proportion of participants on an anti-hypertensive drug at 873 
the time of blood pressure measure ranged between 31% for Asians and 53% for blacks.  874 
Recruitment began in 2011 and is conducted in-person, initiated by an invitation letter and 875 
completed by answering baseline and lifestyle questionnaires, providing a blood sample, 876 
providing access to medical records, and giving permission for re-contact. Consent to participate 877 
is provided after counseling by research staff and mailing of informational materials. All 878 
documents and protocols are approved by the VA Central Institutional Review Board. Blood 879 
samples are collected by phlebotomists and banked at the VA Central Biorepository in Boston, 880 
MA. Genotyping was conducted using a customized Affymetrix Axiom Biobank Array chip with 881 
content added to provide coverage of African and Hispanic haplotypes, as well as markers for 882 
common diseases in the VA population. Researchers are provided with de-identified data, and do 883 
not have the ability or authorization to link these details with a participants’ identity. 884 
MVP Genotype Quality Control 885 
Blood samples drawn from consenting MVP participants were shipped to the Central 886 
Biorepository in Boston, MA, where DNA was extracted and shipped to two external centers for 887 
genotyping on an Affymetrix Axiom Biobank array designed specifically for the MVP. The 888 
MVP genomics working group applied standard quality control and genotype calling algorithms 889 
to the data in batches using the Affymetrix Power Tools Suite (v1.18). Standard quality control 890 
pipelines were used to exclude duplicate samples, samples with more heterozygosity than 891 
expected, samples with an excess (>2.5%) of missing genotype calls, and samples with 892 
discordance of genetically inferred sex versus self-report. We excluded related individuals 893 
(halfway between 2nd and 3rd degree relatives or closer) as measured by the KING software83. 894 
Prior to imputation, variants that were poorly called or that deviated from their expected allele 895 
frequency based on reference data from the 1000 Genomes Project84 were excluded. After pre-896 
phasing using EAGLE v285, genotypes from the 1000 Genomes Project84 phase 3, version 5 897 
reference panel were imputed into Million Veteran Program (MVP) participants via Minimac3 898 
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software86. Principal component analysis was performed using the FlashPCA87, to generate the 899 
top 10 genetic principal components explaining the greatest variability. 900 
Race/ethnicity 901 
Information on race (whites, blacks, Asians, and Native Americans) and ethnicity (Hispanic: Yes 902 
or No) were obtained based on self-report through centralized VA data collection methods using 903 
standardized survey forms, or through the use of information from corporate data warehouse 904 
(CDW), or Observational Medical Outcomes Partnership (OMOP) data, when information from 905 
self-report survey was missing. Race and ethnicity categories were then merged to form the 906 
following race/ethnicity variables: non-Hispanic whites (whites), non-Hispanic blacks (blacks), 907 
non-Hispanic Asians (Asians), non-Hispanic Native Americans (Native Americans) and 908 
Hispanics. Individuals for whom race and ethnicity could not be assigned due to conflicting 909 
records and missing data, were categorized as unknown. Prior to analysis QC, there were 15,710 910 
Veterans with unknown status for race/ethnicity. For these individuals, we used a K-means 911 
clustering approach in R (McQueen algorithm) with the top 10 genetic principal components as 912 
input. To obtain the most reliable cluster designations for the missing data, the K-means 913 
approach was applied to the maximum available samples: the 1000 Genomes reference 914 
populations and all individuals for whom PCs were available regardless of whether race/ethnicity 915 
designations were unknown. K-clusters were optimized by testing values K=2 through K=10. K 916 
= 4 was ultimately chosen as the most optimal value, as visual examination of these most closely 917 
corresponded to whites (N=5,265), blacks (N=4,671), Asians (N= 3,936) and Hispanics (N= 918 
1,838). 919 
MVP Blood Pressure Phenotypes 920 
We selected adults (age ≥ 18) and used the median eligible non-Emergency Department 921 
outpatient measured SBP in the entire available EHR, and used the corresponding DBP from this 922 
measure. In individuals where the median value was observed at multiple clinical encounters on 923 
distinct dates, we used the earliest of those measures to identify the DBP, age, BMI, and anti-924 
hypertensive treatment status of the individual at that time. Measures were ineligible if they 925 
occurred at or after an ICD-9 code from the groups 585 (chronic kidney disease), 405 (secondary 926 
hypertension), or 428 (heart failure). If pain scores were available, blood pressure measures 927 
taken during encounters when a pain score ≥ 5 was recorded were also ineligible, because severe 928 
pain can elevate blood pressure88,89. For measures taken while a patient was on an 929 
antihypertensive medication we added 15 mmHg to SBP and 10 mmHg to DBP8,90. 930 
MVP Analysis 931 
For the MVP GWAS we performed linear regression association tests with additive models for 932 
untransformed blood pressure traits, after adjusting for medication use. We adjusted linear 933 
regression models analyzing SNP associations for age at blood pressure measure, age2, sex, BMI 934 
measured within 1 year of blood pressure measure, and the top 10 genetic principal components 935 
in analyses. All primary analyses for the MVP were conducted by either strata of 936 
administratively assigned race/ethnicity or by their empirically designated clusters. All 937 
regression based analyses were conducted in SNPTEST-v2.5.4-beta91. Inference was limited to 938 
genotyped and imputed variants with SNPTEST Info scores of 0.4 or higher, with Hardy 939 
Weinberg equilibrium P-value > 5 × 10-8 for common variant analysis (minor allele frequency > 940 
0.1). Inference on rare variants, SNPs with MAF ≤ 1%, was restricted to variants with an 941 
effective minor allele count (SNPTEST Info score multiplied by minor allele count) of ≥10 in 942 
each analysis sub-cohort.  943 
The UK Biobank 944 
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Summary statistics from the analysis of the interim data from the UK Biobank (UKB) were 945 
utilized in our meta-analysis. These results have been previously reported by Warren et al.12. 946 
Briefly, following central and study-specific quality control protocols, 140,886 empirically 947 
classified white individuals were analyzed for SBP, DBP, and pulse pressure traits. Blood 948 
pressure measures were averaged over two measures, and adjusted for medication use by adding 949 
15 and 10 mmHg to SBP and DBP, respectively. Linear models were adjusted for the top 10 950 
principal components of ancestry, age, age2, sex, an indicator for genotyping platform, and BMI.   951 
Meta-Analysis of Discovery Datasets 952 
Inverse-variance weighted fixed-effects meta-analysis of common variants across MVP subsets 953 
and summary statistics from UKB was performed using the METAL software. Genomic inflation 954 
factor was calculated, and λGC for the discovery from MVP were 1.195, 1.149, and 1.171 for 955 
SBP, DBP and pulse pressure, respectively, 1.303, 1.315, and 1.270 respectively, from UKB, and 956 
1.275, 1.140, and 1.244, respectively, in the overall discovery analysis (Supplementary Figure 957 
10). Subsequently, we utilized the LD Score Regression approach92 to ascertain whether inflation 958 
was due to residual population stratification or polygenicity. Calculation of the intercept in the 959 
MVP Whites discovery analysis dataset were 1.05 (standard error = 0.01), 1.03 (standard error = 960 
0.01), and 1.04 (standard error = 0.01), for SBP, DBP, and pulse pressure respectively, 961 
suggesting that little of the observed inflation in the lambda is due to population stratification. 962 
Selection of SNPs for Replication 963 
Common Variants 964 
For common variants, we considered for follow-up SNPs in loci non-overlapping with 965 
previously reported loci according to both an LD threshold of r2 ≤ 0.1 and a 1Mb interval. We 966 
obtained a list of these SNPs with P-value < 1 × 10-6 for any of the three blood pressure traits, a 967 
minor allele frequency (MAF) ≥ 1%, and concordant directions of effect between UKB and 968 
MVP. 969 
In silico replication summary statistics were provided for 942 SNPs by the International 970 
Consortium for Blood Pressure Genetics (ICBP)25 after meta-analysis of 77 individual 971 
participating cohorts for a total maximum of 299K individuals, who were genotyped and 972 
analyzed according to study-specific protocols. Additional replication results were provided from 973 
Vanderbilt University’s BioVU EMR-linked biorepository, among which genotypes from the 974 
MEGA array and phenotype data were available from 17,277 participants. Discovery and 975 
replication data were combined using fixed-effects inverse-variance weighted meta-analysis 976 
implemented in METAL93. 977 
Rare Variants 978 
We conducted an in silico replication analysis of 18 rare exonic SNPs from our discovery 979 
analysis in 417,143 participants from the BP-ICE consortium. SNPs were chosen for replication 980 
if they had a discovery P-value < 1 × 10-6, and a MAF < 1%.  981 
BP-ICE used the exome array and did not have genome wide coverage of rare variants. 982 
Therefore, we also pursued replication utilizing the full release of the UKB data to capture non-983 
exonic rare variation. Due to the inclusion of UKB data in the discovery set, for the second 984 
analysis we sought replication from variants suggestive only in MVP cohorts following meta-985 
analysis as described above. 1,066 rare variants with P-value < 1 × 10-6 for any of the three 986 
phenotypes were selected for replication in 458,577 participants from UKB.  Additional 987 
replication was provided from BioVU MEGA, and all data were meta-analyzed using fixed-988 
effects meta-analysis in METAL93. 989 
Classifying Results by Evidence for Association 990 
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For results that reached statistical significance of P-value ≤ 5 × 10-8 after final meta-analysis, and 991 
that had consistent direction of effect between discovery and replication stages, we established 992 
three tiers of evidence that are annotated in results tables (Supplementary Tables 3a-c): 993 
1) Genome-wide significance in the discovery stage, and Bonferroni-corrected significance 994 
in replication and consistent trait-specific direction of effect across stages. 995 
2) Genome-wide significance in the discovery stage, and P-value ≤ 0.05 in the replication 996 
stage and consistent trait-specific direction of effect across stages 997 
3) Variants had P-value less than 1 × 10-6 and > 5 × 10-8 in the discovery stage, and had P-998 
value < 0.05 in the replication stage and had consistent trait-specific direction of effect 999 
across stages and was genome-wide significant after final analysis.  1000 
Conditional Analysis 1001 
For conditional analysis of common variants we used two parallel approaches implemented in 1002 
the Genome-wide Complex Traits Analysis (GCTA) software94. Details are described in the 1003 
Supplementary Note. 1004 
Proportion of Variance Explained 1005 
We approximated the proportion of blood pressure-trait specific variance explained in the trans-1006 
ethnic meta-analysis by all independent sentinel SNPs (novel and known) and novel SNPs, 1007 
separately. Variance explained by each SNP was first estimated by the following equation: 1008 
ݎଶ = χ
ଶ
n  
The sum of the variances of the independent sentinel SNPs for common variants provided 1009 
estimates for the proportion of variance explained for all SNPs, and novel SNPs for each of the 1010 
blood pressure traits. The transformation of the relationship between t-statistic and r2 to χଶ 1011 
statistic to r2 is described in Supplementary Note.  1012 
Genetic Risk Score Construction 1013 
We constructed a genetic risk score (GRS) for each blood pressure trait by calculating a linear 1014 
combination of weights derived from the 140,886 participants from the UKB common variant 1015 
analysis and sentinel SNPs at each statistically significant locus observed in the MVP. Weighted 1016 
GRS (w-GRS) were constructed for self-reported/administratively assigned non-Hispanic whites, 1017 
blacks and Hispanics in the MVP.   1018 
Phenome Wide Association Study Analysis 1019 
We performed a phenome-wide association study (PheWAS)95 of GRS for each blood pressure 1020 
trait in MVP whites (Nmax = 188,088), blacks (Nmax = 52,530), and Hispanics (Nmax = 16,735), 1021 
leveraging the diverse nature of MVP as well as the full catalog of ICD-9 diagnosis codes. We 1022 
used logistic regression to separately model up to 1,813 PheWAS traits as a function of the three 1023 
GRSs, adjusted for age, age2, sex, BMI, and 10 PCs. We report the results from these analyses as 1024 
odds ratios where the estimate is the average change in odds of the PheWAS trait per weighted 1025 
blood pressure-increasing allele. Interpretation of results were limited to phenotypes with 25 or 1026 
more cases. Multiple testing thresholds for statistical significance were set to P-value ≤ 2.75 × 1027 
10-5 (0.05/1,813). All PheWAS analyses were conducted using the R PheWAS package96. Effect-1028 
estimates from significant PheWAS results from any one or more of the analysis were then 1029 
compared between whites, blacks and Hispanics to report Pearson’s correlations (R2) for each 1030 
pair per trait (Supplementary Figure 5).  1031 
S-PrediXcan Analysis 1032 
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Genetically predicted gene expression was evaluated for the common variant subset with S-1033 
PrediXcan31, a gene-level approach which estimates the genetically determined component of 1034 
gene expression in a given tissue and tests it for association with SNP-level summary statistics. 1035 
We utilized all three blood pressure meta-analysis results for common variants and 44 tissues 1036 
from GTEx36 for this analysis, as well as the collection of kidney reference data that was recently 1037 
described by Ko et al.37, incorporating covariance matrices developed for European populations 1038 
(1000 Genomes) as the majority of samples were European in origin.  1039 
Evaluation of Kidney Loci in Murine Kidneys 1040 
For the genes implicated by the S-PrediXcan analysis as having associated expression in kidney, 1041 
we evaluated homologous genes in the single cell atlas of the mouse kidney, where expression 1042 
levels are measured by single-cell RNAseq across 57,979 total mouse kidney cells from 7 1043 
healthy mice97. This enables us to observe what cell types in the mammalian kidney express the 1044 
genes where there is evidence for association between expression and blood pressure traits. After 1045 
quality filtering steps, a single cell-gene matrix containing the UMI (unique molecular identifier) 1046 
counts for 43,745 cells and 16,273 transcripts were generated from 7 normal mouse kidneys 1047 
using 10x ChromiumTM Single cell solution97. Mouse homologs of the target human genes 1048 
identified by the S-PrediXcan analysis were found using Ensembl BioMart. Genes that expressed 1049 
less than 5% of the cell clusters were excluded from analysis. To calculate the average 1050 
expression level for each cluster, a z-score of UMI count was first obtained for every single cell. 1051 
Then, we calculated the mean z-scores for individual cells in the same cluster, resulting in z-1052 
score for each gene and each cell cluster.  1053 
Evaluation of Drug Classes for Genes with Associations with Gene Expression 1054 
To better understand the performance of the S-PrediXcan method, identify genes with potential 1055 
to be leads for drug development, and identify drug-gene pairs that may be leads for repurposing, 1056 
three comparisons were made among significant associations from S-PrediXcan analyses. 1) We 1057 
identified all S-PrediXcan genes that are targeted by an antihypertensive drug to validate 1058 
associations and identify the most credible genes in regions with many associations. 2) We 1059 
provide a list of candidate genes that are potential leads for novel inhibitory antihypertensive 1060 
therapies by considering genes with positive effects for GPGE on blood pressure that are also 1061 
targeted by a non-antihypertensive drug. 3) To identify genes that may be leads for developing 1062 
novel treatments and drugs with repurposing potential, we report gene-drug pairs for significant 1063 
S-PrediXcan genes that are not targeted by an antihypertensive drug, but are targeted by a drug 1064 
with a toxicity that involves hyper- or hypotension. 1065 
A list of medications with a primary indication for hypertension and a list of medications with 1066 
adverse drug events (ADEs) of hypertension or hypotension were created using SIDER98 and the 1067 
DEB2 database99. Gene targets for antihypertension medications, medications targeting genes 1068 
significant in S-PrediXcan analyses with positive effect sizes, and medications targeting genes 1069 
mapped from significant GWAS signals were queried using DGIdb100. Primary indications for 1070 
medications targeting genes significant in S-PrediXcan analyses with positive effect sizes were 1071 
compiled using the BIDD TTD database101.   1072 
To identify genes that are attractive leads for novel inhibitory drugs, we report significant S-1073 
PrediXcan genes with a positive effect size (i.e. increasing gene expression is associated with 1074 
increasing one or more blood pressure traits) that are targeted by a non-antihypertensive 1075 
medication without an indication of ADEs for hypertension or hypotension. This list thereby 1076 
represents a set of genes that are both likely to be involved in blood pressure regulation in one or 1077 
more tissues, and can be targeted by drugs. Known targets for anti-hypertensive drugs significant 1078 
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by S-PrediXcan and a summary of the most significant S-PrediXcan result across tissues and 1079 
blood pressure traits is presented in Supplementary Table 11. Significant S-PrediXcan genes that 1080 
have positive effect sizes in any tissue and are targeted by a non-hypertension drug with no ADE 1081 
for hypertension or hypotension are presented in Supplementary Table 12.  1082 
We report another group of genes that may be attractive for treatment development, on the basis 1083 
of being both associated with blood pressure traits and targeted by non-antihypertensive drugs 1084 
that feature an ADE of either hypo- or hypertension. These gene-drug pairs may be leads for 1085 
either modification of drug molecules, modification of dosing or delivery strategies, or potential 1086 
gene targeting by novel treatments. Genes that are significant by S-PrediXcan, are targeted by a 1087 
drug, and that have an ADE involving hypertension or hypotension are presented in 1088 
Supplementary Table 13. Gene-drug relationships for all genes mapped from significant 1089 
association signals are presented in Supplementary Table 14.  1090 
Enrichment and Pathway Analyses  1091 
We investigated whether one or more of the 45 tissues evaluated with S-PrediXcan were 1092 
enriched. We also performed enrichment analyses in DEPICT39 by using trait-specific GWAS 1093 
significant sentinel SNPs as input. We evaluated significant genes from the top enriched S-1094 
PrediXcan tissue (aorta) for each trait with the Ingenuity Pathway Analysis (IPA) software 1095 
(IPA®,QIAGEN Redwood City) (Supplementary Figures 7-9 and Supplementary Note).  1096 
Ethics statement 1097 
The central Veterans Affairs Institutional Review Board (IRB) and site-specific IRBs approved 1098 
the Million Veteran Program study. The Vanderbilt University Medical Center IRB approved the 1099 
use of BioVU data for this study. Each cohort within the ICBP and BP-ICE consortiums have 1100 
ethical approval from their local institution. All relevant ethical regulations were followed.  1101 
Reporting Summary 1102 
 1103 
Further information on research design is available in the Life Sciences Reporting Summary 1104 
linked to this article.  1105 
 1106 
DATA AVAILABILITY STATEMENT 1107 
Full summary statistics relating to the Million Veteran Program (MVP) are publically available 1108 
and may be accessed here with the accession code phs001672.v1.p1: 1109 
https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001672.v1.p1. The 1110 
UK BioBank data are available upon application to the UKBiobank 1111 
(https://www.ukbiobank.ac.uk). Combined summary statistics for common and rare variant 1112 
analysis (discovery + replication) for sentinel SNPs for each blood pressure-trait, are available in 1113 
supplementary tables. Statistically significant reports for S-PrediXcan results for all 45 tissues 1114 
and PheWAS analyses for all blood pressure-traits evaluated are also made available in the 1115 
Supplementary Tables. Murine single-cell sequencing data can be found under GEO 1116 
(GSE107585).  1117 
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Editorial summary:  1172 
Analysis of blood pressure data from the Million Veteran Program trans-ethnic cohort identifies 1173 
common and rare variants, and genetically predicted gene expression across multiple tissues 1174 
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 1176 
